Literature DB >> 12601490

Steady-state sVCAM-1 serum levels in adults with sickle cell disease.

J B Schnog1,2,3, R A Rojer4, M R Mac Gillavry5, H Ten Cate5, D P M Brandjes5, A J Duits6.   

Abstract

Cytokines and adhesion molecules play an important role in the pathophysiology of vaso-occlusion in sickle cell disease (SCD), and their in vivo profiles are potential tools for assessing SCD severity. We compared steady-state soluble vascular cell adhesion molecule-1 (sVCAM-1) serum levels to clinical (painful crisis frequency, occurrence of acute chest syndrome, leg ulcers, and cerebrovascular disease) and related hematological parameters of SCD severity (such as HbF%, hemoglobin levels, and leukocyte counts) in 29 HbSS adults. Serum sVCAM-1 levels were not related to clinical severity, but an inverse correlation was demonstrated between sVCAM-1 and hemoglobin levels (r=-0.71, p<0.001) with a positive correlation to serum lactate dehydrogenase levels (r=0.59, p=0.008). Based upon these results, steady-state serum sVCAM-1 levels do not seem to reflect clinical disease severity. However, as VCAM-1 is involved in hematopoiesis, sVCAM-1 levels might reflect bone marrow activity in SCD. This underlies the pleiotropic nature of adhesion molecules in vivo and the need for further research in this area, especially since therapies targeting (cellular) adhesive interactions involving the endothelium are emerging for SCD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12601490     DOI: 10.1007/s00277-003-0609-1

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  11 in total

1.  Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality.

Authors:  Gregory J Kato; Sabrina Martyr; William C Blackwelder; James S Nichols; Wynona A Coles; Lori A Hunter; Marie-Luise Brennan; Stanley L Hazen; Mark T Gladwin
Journal:  Br J Haematol       Date:  2005-09       Impact factor: 6.998

2.  Renal vascular resistance in sickle cell painful crisis.

Authors:  Birol Guvenc; Kairgeldy Aikimbaev; Cagatay Unsal; Erol Akgul; A Erol Akgul; Figen Binokay; Ayberk Besena
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

3.  Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease.

Authors:  Gregory J Kato; Vicki McGowan; Roberto F Machado; Jane A Little; James Taylor; Claudia R Morris; James S Nichols; Xunde Wang; Mirjana Poljakovic; Sidney M Morris; Mark T Gladwin
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

4.  Inhaled steroids reduce pain and sVCAM levels in individuals with sickle cell disease: A triple-blind, randomized trial.

Authors:  Jeffrey Glassberg; Caterina Minnitti; Caroline Cromwell; Lawrence Cytryn; Thomas Kraus; Gwen S Skloot; Jason T Connor; Adeeb H Rahman; William J Meurer
Journal:  Am J Hematol       Date:  2017-06-05       Impact factor: 10.047

Review 5.  Pleiotropic effects of intravascular haemolysis on vascular homeostasis.

Authors:  Gregory J Kato; James G Taylor
Journal:  Br J Haematol       Date:  2009-12-01       Impact factor: 6.998

6.  Vascular dysfunction in a murine model of severe hemolysis.

Authors:  Anne C Frei; YiHe Guo; Deron W Jones; Kirkwood A Pritchard; Karen A Fagan; Neil Hogg; Nancy J Wandersee
Journal:  Blood       Date:  2008-05-13       Impact factor: 22.113

7.  The acute phase inflammatory response to maximal exercise testing in children and young adults with sickle cell anaemia.

Authors:  Robert I Liem; Kasiemobi Onyejekwe; Marie Olszewski; Chisalu Nchekwube; Frank P Zaldivar; Shlomit Radom-Aizik; Mark J Rodeghier; Alexis A Thompson
Journal:  Br J Haematol       Date:  2015-10-12       Impact factor: 6.998

Review 8.  Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy.

Authors:  Gregory J Kato; Mark T Gladwin
Journal:  JAMA       Date:  2008-12-10       Impact factor: 56.272

9.  Application of phospho-CyTOF to characterize immune activation in patients with sickle cell disease in an ex vivo model of thrombosis.

Authors:  Jeffrey Glassberg; Adeeb H Rahman; Mohammad Zafar; Caroline Cromwell; Alexa Punzalan; Juan Jose Badimon; Louis Aledort
Journal:  J Immunol Methods       Date:  2017-07-29       Impact factor: 2.303

Review 10.  Sickle cell vaso-occlusion: The dialectic between red cells and white cells.

Authors:  Nicola Conran; Stephen H Embury
Journal:  Exp Biol Med (Maywood)       Date:  2021-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.